DURECT Corporation (NASDAQ:DRRX) is set to release its earnings data after the market closes on Tuesday, August 8th. Analysts expect DURECT Corporation to post earnings of ($0.05) per share for the quarter.

DURECT Corporation (NASDAQ:DRRX) last announced its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of $4.57 million for the quarter, compared to analysts’ expectations of $3.60 million. DURECT Corporation had a negative return on equity of 318.49% and a negative net margin of 232.05%. On average, analysts expect DURECT Corporation to post $-0.19 EPS for the current fiscal year and $-0.15 EPS for the next fiscal year.

Shares of DURECT Corporation (NASDAQ DRRX) opened at 1.69 on Friday. The company’s market cap is $239.92 million. The stock’s 50 day moving average price is $1.62 and its 200 day moving average price is $1.19. DURECT Corporation has a one year low of $0.74 and a one year high of $1.95.

TRADEMARK VIOLATION WARNING: “DURECT Corporation (NASDAQ:DRRX) Scheduled to Post Earnings on Tuesday” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/06/durect-corporation-nasdaqdrrx-scheduled-to-post-earnings-on-tuesday.html.

Several equities analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of DURECT Corporation in a research note on Monday, May 22nd. Stifel Nicolaus upgraded DURECT Corporation from a “hold” rating to a “buy” rating and lifted their price target for the company from $1.25 to $3.00 in a research note on Wednesday, July 12th.

DURECT Corporation Company Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Earnings History for DURECT Corporation (NASDAQ:DRRX)

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.